

About the Kaiser Family Foundation (KFF)

KFF is a non-profit, non-grantmaking organization focusing on national health issues, and the U.S. role in global health policy


KFF serves as a non-partisan source of facts, analysis and journalism for policymakers, the media, the health policy community and the public

Headquartered in San Francisco, with a Washington DC office

KFF is not associated with Kaiser Permanente





Most Proposals For Lowering Prescription Drug Costs Are Popular Across Parties						
% who strongly/somewhat favor each of the following:	Total	Democrats	Independents	Republica		
Allowing the government to negotiate with drug companies to get a lower price for people on Medicare	88%	92%	90%	85%		
Allowing the government to negotiate with drug companies to get a lower price for both Medicare and private insurance	85	94	84	84		
Placing an annual limit on out-of-pocket costs for seniors enrolled in Medicare Part D plans	81	83	81	82		
Allowing Americans to buy prescription drugs imported from licensed Canadian pharmacies	78	75	82	75		
Allowing Medicare to place limits on how much drug companies can increase the price of drugs based on annual inflation rates	76	78	77	77		
Increasing taxes on drug companies that refuse to negotiate the price of medications with the federal government	72	79	71	69		
Lowering what Medicare pays for some drugs based on amounts in other countries where governments more closely control prices	62	73	62	52		



	House (H.R. 3)	Senate Finance	Trump Administration	
Medicare Part D benefit redesign with limit on out-of-pocket costs	✓	✓	✓	
HHS Secretary negotiates drug prices	✓	x	X	
Inflation-based limit on drug prices	✓	~	✓	







	House (H.R. 3)	Senate Finance	Trump Administration
Medicare Part D benefit redesign with limit on out-of-pocket costs	✓	✓	✓
HHS Secretary negotiates drug prices	~	x	X
Inflation-based limit on drug prices	✓	~	✓




Figure 10 How Would P	roposals Use Ir Price Incre		o Limit Drug		
	House (H.R. 3)	Senate Finance	Trump Administration		
Applies to Part B/Part D	Both	Both	Part B only		
Applies to all drugs (brands/generics)	Part B: brands, biologics, and biosimilars Part D: All drugs	Brands and biologics only	Not specified		
Require rebate for drug price increases faster than inflation	×	✓ Not applicable			
Penalty if rebate not paid within 30 days	Rebate + 25%	Rebate + 25% Not applicabl			
Base year for determining inflation-adjusted price	2016	2019	2018		
*Under this proposal, outlined in the Pro adjusted price, so rebates would not be		d not pay more for a Part B drug th	han the inflation-		

